Stocks · News reference
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Compass Therapeutics Announces Participation in Upcoming Investor Events
Compass Therapeutics, Inc. announced its participation in upcoming investor events scheduled for November 2026.
This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.